A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model

Fudenberg HH, Drews G, Nisonoff A (1964) Serologic demonstration of dual specificity of rabbit bivalent hybrid antibody. J Exp Med 119(1):151–166 Jiabiang Ma et al (2021) Bispecific antibodies: from research to clinical application front. Immunol 12:1555 Segal DM, Weiner GJ, Weiner LM (1999) Bispecific antibodies in cancer therapy. Curr Opin Immunol 11:558–562 Liu L, Lam CK, Long V, Widjaja L, Yang Y, Li H, Jin L, Burke S, Gorlatov S, et. Al, (2017) MGD011, A CD19 x CD3 dual-affinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies. Clin Cancer Res 23(6):1506–1518 Choi BD, Cai M, Bigner DD, Mehta AI, Kuan CT, Sampson JH (2011) Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther 11:843–853 Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, Noppeney R, Hess G, Kallert S et al (2016) Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol 34(10):1104–1111 Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, Doshi S (2016) Blinatumomab, a bispecific T-cell engager (BiTE(®)) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications. Clin Pharmacokinet 55(10):1271–1288 Jacoby E (2019) Relapse and resistance to CAR-T cells and blinatumomab in hematologic malignancies. Clin Hematol Int 1(2):79–84 Myers RM, Taraseviciute A, Steinberg SM et al (2022) Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-all. J Clin Oncol 40(9):932–944 Braig F, Brandt A, Goebeler M, Tony H-P, Kurze A-K, Nollau P et al (2017) Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood 129:100–104 Sotillo E, Al (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 Immunotherapy. Cancer Discov 5(12):1282–1295 Amgen, Data on file. https://www.blincytohcp.com/rr/safety/adult?gclid=CjwKCAjw2rmWBhB4EiwAiJ0mte8Vn4fxhC6Wi7kVyQ8R-vsMZIx7hnAh-sem_410FC69bQxDP-KKjRoCcF0QAvD_BwE&gclsrc=aw.ds. Accessed 12 July 2022 Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS et al (2022) Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol 40(5):481–491 Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner F, Sureda A, Salles G et al (2021) Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol 39(18):1959–1970 Shah NN et al (2015) Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer 62(6):964–969 Clark EA, Giltiay NV (2018) CD22: a regulator of innate and adaptive B cell responses and autoimmunity. Front Immunol 9:2235 Clark EA (1993) CD22, a B cell-specific receptor, mediates adhesion and signal transduction. J Immunol 150:4715–4718 Nitschke L et al (1997) CD22 is a negative regulator of B-cell receptor signaling. Curr Biol 7(2):133–143 Yoshida S et al (2017) Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia. Leuk Lymphoma 58(5):1254–1257 Kantarjian HM, DeAngelo DJ, Stelljes M et al (2019) Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer 125(14):2474–2487 O’Donnell RT et al (2009) Treatment of non-Hodgkin’s lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy. Cancer Immunol Immunother 58(10):1715–1722 O’Donnell RT et al (2009) Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-Hodgkin’s lymphoma cells. Leuk Res 33(7):964–969 Spiegel JY, Patel S, Muffly L et al (2021) CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med 27:1419–1431 Martin SM et al (2011) The HB2.27 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner. J Hematol Oncol 4:49 Wudhikarn K, King AC, Geyer MB, Roshal M, Bernal Y, Gyurkocza B, Perales M-A, Park JH (2022) Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab. Blood Adv 6(5):1432–1443 Zhang Y, Li S, Wang Y et al (2022) A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy. Exp Hematol Oncol 11:15 Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM et al (2000) A recombinant bispecific single-chain antibody, CD19XCD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:6 Engel P, Nojima Y, Rothstein D, Zhou LJ, Wilson GL, Kehrl JH, Tedder TF (1993) The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes. J Immunol 150(11):4719–4732 Dreier T, Baeuerle PA, Iduna F, Grün M, Schlereth B, Lorenczewski G et al (2003) T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3—bispecific single-chain antibody construct. J Immunol 170:4397–4402 Rossi DL, Rossi EA, Cardillo TM, Goldenberg DM, Chang CH (2014) A new class of bispecific antibodies to redirect T cells for cancer immunotherapy. MAbs 6(2):381–391. https://doi.org/10.4161/mabs.27385 Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH et al (2013) Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121(7):1165–1174 Du X, Beers R, Fitzgerald DJ, Pastan I (2008) Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res 68(15):6300–6305 Nagorsen D, Kufer P, Baeuerle PA, Bargou R (2012) Blinatumomab: a historical perspective. Pharmacol Ther 136(3):335 Pan J, Niu Q, Deng B, Liu S, Wu T, Gao Z, Liu Z, Zhang Y, Qu X, Zhang Y, Liu S, Ling Z, Lin Y et al (2019) CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia 33(12):2854–2866 Mehta NK, Pfluegler M, Meetze K et al (2022) A novel IgGbased FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL. J Immunother Cancer 10:e003882 Schneider D, Xiong Y, Wu D, Hu P, Alabanza L et al (2021) Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci Transl Med 13(586):eabc6401 Smith EJ et al (2015) A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep 5:17943. https://doi.org/10.1038/srep17943 Wang S, Peng L, Xu W, Zhou Y, Zhu Z, Kong Y, Leung S, Wang J, Yan X, Mi JQ (2022) Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia. Front Med 16(1):139–149 Janssen Trial. https://clinicaltrials.gov/ct2/show/NCT04540796 Zhang J, Zhou Z (2020) Preclinical study of a novel tri-specific anti-cd3/cd19/cd20 T cell-engaging antibody as a potentially better treatment for NHL. Blood 136 (Supplement 1):22. https://doi.org/10.1182/blood-2020-140154